Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 43Colorectal Neoplasms 32Stomach Neoplasms 28Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Head and Neck Neoplasms 12Advanced Solid Tumor 12Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Nasopharyngeal Carcinoma 10Cholangiocarcinoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Melanoma 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

tislelizumab 2Cystectomy 2vistusertib 1toripalimab 1olaparib 1liposomal doxorubicin 1durvalumab 1disitamab vedotin 1danvatirsen 1adavosertib 1Surgical Procedures, Operative 1Rutin 1Radiation 1RC48 antibody 1Neoadjuvant Therapy 1Gemcitabine 1Cisplatin 1Chemoradiotherapy 1AZD4547 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Muscle Invasive Bladder Cancer × tislelizumab × Clear all
NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

First Affiliated Hospital of Chongqing Medical University

Phase 1 Recruiting
10 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown
79 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡